This site is optimised for modern browsers. For the best experience, please use Google Chrome, Mozilla Firefox, or Microsoft Edge.

RECOVERY-RS: Randomised Evaluation of COVID-19 Therapy - Respiratory Support (Video transcript)

Contents

RECOVERY-RS: Randomised Evaluation of COVID-19 Therapy - Respiratory Support

Patients with severe symptoms of COVID-19 may require respiratory support to help get more oxygen into their lungs.

The RECOVERY-RS trial aims to compare three methods of doing this:

  1. Continuous positive airway pressure (CPAP);
  2. High flow nasal oxygen (HFNO);
  3. Oxygen therapy only

International guidelines about using these treatments are currently conflicting.

But with research, we can find out which treatment gives the best outcome for patients.

The RECOVERY-RS trial aims to provide much-needed evidence to answer this question.

It is funded and supported by the NIHR and considered an urgent public health study by the UK's Chief Medical Officers because of its high importance for the future treatment of UK and global patients.

More hospitals are needed to help gather this vital information.

“We simply do not know what treatments are effective for this new disease. We urgently need this trial to test what is the best way to deliver respiratory support as an alternative to ventilators.” - Prof Danny McAuley and Prof Gavin Perkins, Co-Chief Investigators

Find out more about this important research: RECOVERY-RS website

Logos: National Institute for Health Research; Warwick Clinical Trials Unit; Queen’s university Belfast; University Hospitals Birmingham NHS Foundation Trust Intensive Care Society.